Oncotarget

Research Papers:

CEBPD amplification and overexpression in urothelial carcinoma: a driver of tumor metastasis indicating adverse prognosis

Yu-Hui Wang, Wen-Jeng Wu, Wei-Jan Wang, Hsuan-Ying Huang, Wei-Ming Li, Bi-Wen Yeh, Ting-Feng Wu, Yow-Ling Shiue, Jim Jinn-Chyuan Sheu, Ju-Ming Wang and Chien-Feng Li _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:31069-31084. https://doi.org/10.18632/oncotarget.5209

Metrics: PDF 1153 views  |   HTML 1351 views  |   ?  


Abstract

Yu-Hui Wang1,2, Wen-Jeng Wu3,4,5,6,7, Wei-Jan Wang2, Hsuan-Ying Huang8, Wei-Ming Li3,4,5, Bi-Wen Yeh4,5,7, Ting-Feng Wu9, Yow-Ling Shiue10, Jim Jinn-Chyuan Sheu10,*, Ju-Ming Wang2,*, Chien-Feng Li8,9,11,12,13,*

Department of Pathology, Chi-Mei Medical Center, Tainan, Taiwan

Institute of Bioinformatics and Biosignal Transduction, National Cheng Kung University, Tainan, Taiwan

Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan

Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan

Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan

Department of Urology, Kaohsiung Municipal Hsiao-Kang Hospital, Kaohsiung, Taiwan

Center for Stem Cell Research, Kaohsiung Medical University, Kaohsiung, Taiwan.

Department of Pathology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan

Department of Biotechnology, Southern Taiwan University of Science and Technology, Tainan, Taiwan

10 Institute of Biomedical Science, National Sun Yat-Sen University, Kaohsiung, Taiwan

11 National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan

12 Institute of Clinical Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan

13 Department of Internal Medicine and Cancer Center, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan

* These authors contributed equally as senior authors of this work

Correspondence to:

Chien-Feng Li, email:

Keywords: urothelial carcinoma, 8q, CEBPD, amplification, MMP2

Received: May 03, 2015 Accepted: August 11, 2015 Published: August 17, 2015

Abstract

The molecular aberrations responsible for the progression of urothelial carcinoma (UC) remain largely obscure. To search candidate driver oncogenes in UC, we performed array-based genomic hybridization (aCGH) on 40 UBUC samples. Amplification of 8q11.21 was preferentially identified in patients who developed disease-specific death (53.8%) and distal metastasis (50.0%) but was barely detected in non-eventful cases (3.7% and 0%, respectively). In order to quantify the expression of candidate genes harbored in 8q11.21, laser-capture microdissection coupled with RT-PCR was performed on 32 of the 40 cases submitted to aCGH. With this, we identified CEBPD mRNA expression as most significantly associated with gains of 8q11.21, suggesting amplification-driven expression. By performing CEBPD-specific FISH and immunohistochemistry on 295 UBUCs, we confirmed CEBPD amplification (21.3%) and overexpression (29.8%) were strongly related to each other (p<0.001). Moreover, both were associated with adverse clinicopathologic features and worse outcomes. Furthermore, the clinical significance of CEBPD expression was also confirmed in an independent cohort comprised of 340 UCs from the upper urinary tract. Interestingly, CEBPD knockdown suppressed cell proliferation, migration and, most significantly, cell invasion ability in UC cells. The latter phenotype is attributed to downregulation of MMP2 as identified by RT2 Profiler PCR array. Moreover, expression of CEBPD significantly enhanced MMP2 expression and transcriptional activation by directly binding to its promoter region, as confirmed by promoter reporter assay and chromatin immunoprecipitation assay. Conclusively, CEBPD amplification is a mechanism driving increased mRNA and protein expression that confers aggressiveness in UC through MMP2-mediated cell invasiveness.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 5209